Neomorph

Executive Summary

Neomorph is a venture-backed biotechnology company based in San Diego, California, focused on discovering and developing targeted protein degradation (TPD) therapies, with a particular emphasis on molecular glue degraders. Founded in 2020, the company aims to address 'undruggable' disease targets by leveraging the ubiquitin-proteasome system to eliminate disease-causing proteins. Neomorph's approach combines proprietary screening platforms and structure-based design to identify novel molecular glues that induce proximity between a target protein and an E3 ligase, leading to degradation. The company has advanced a pipeline of programs into clinical development, with a patient-first, science-driven strategy. Although specific pipeline details are not publicly disclosed, Neomorph is operating in the highly active TPD space, which has attracted significant interest from large pharma. The company's platform has potential applicability across oncology, immunology, and neurology, and its early-stage clinical data will be critical in validating its technology and differentiation from competitors. Neomorph is currently in Phase 1/2 clinical trials, likely evaluating its lead molecular glue degrader candidates. The company's progress is closely watched given the broader success of TPD modalities and the unique advantages of molecular glues over traditional PROTACs, such as oral bioavailability and ability to target previously inaccessible proteins. Key upcoming catalysts include initial clinical data readouts from ongoing Phase 1/2 studies, which could demonstrate proof-of-mechanism and early efficacy signals. Additionally, potential business development activities, such as strategic partnerships or licensing deals with major pharmaceutical companies, could provide validation and non-dilutive funding. Financing events, including a potential Series C or crossover round, may also be on the horizon to support pipeline expansion and late-stage development. Neomorph's conviction score remains high, supported by strong investor interest, a seasoned management team, and the growing demand for novel protein degradation therapies.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1/2 Clinical Data Readout60% success
• Q2 2026Strategic Partnership or Licensing Deal50% success
• Q3 2026Series C or Crossover Financing Round70% success